
    
      1. To establish standard risk rating criteria of aGVHD biomarkers;

        2. To verify the role of aGVHD biomarkers monitored in predicting aGVHD risks;

        3. To determine the correlation between aGVHD biomarkers monitored and aGVHD risk;

        4. To carry out a observative study in patients with aGVHD treatment about therapeutic
           protocols and medication efficacy;

        5. To predict the correlation between the high-risk patients with aGVHD and non-relapse
           mortality and disease free survival;
    
  